Komori
Astellas Pharma (4503) · Initiative事業譲渡に伴う減損損失の計上

Business Transfer of the Nishine Plant

First written in FY2019-Q3. . Latest entry: FY2019-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Impairment Associated with the Transfer of the Nishine Plant's BusinessA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2019-Q3事業譲渡に伴う減損損失の計上Annual report

    「また、「その他の費用」として、国内事業再編等に伴うリストラクチャリング費用のほか、訴訟関係費用、開発プロジェクトの中止及び西根工場の事業譲渡に伴う減損損失等を計上しました。」

    西根工場の事業譲渡に伴う減損損失を計上したことが初めて開示された。本文では譲渡先や完了時期などの詳細は示されていない。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.